



Practical Guidance for the Community Oncologist Incorporating Advances in Therapy for Metastatic TNBC: A Focus on TROP2

Host a complimentary Virtual Visiting Professorship Program to learn about the emergence of TROP2-directed antibody drug conjugate (ADC) technology for promising new targeted treatment approaches for patients with triple negative breast cancer (TNBC).

Topic Highlights

- ▶ TNBC treatment challenges
- ▶ ADC mechanistic rationale
- ▶ Role of TROP2 in TNBC
- ▶ Case-based application of current data and recommendations

Live interaction with a leading expert

CHAIR



Hope Rugo, MD, FASCO
Professor of Medicine
San Francisco, CA

FEATURED FACULTY



Sara Hurvitz, MD, FACP
Professor of Medicine
Los Angeles, CA



Sara Tolaney, MD, MPH
Associate Professor of Medicine
Boston, MA



Ruta Rao, MD
Professor of Medicine
Chicago, IL



Stephanie Graff, MD, FACP
Brown University
Providence, RI

For more information and to schedule a course at your institution, contact:
Michelle Forcier (mforcier@achlcme.org) 773.714.0705 x118